Cameron Fick, MD
Hospital ResidentCards
About
Research
Publications
2024
Coding the issue: low anterior resection syndrome following rectal cancer treatment
Fick C, Linhares S, Schultz K, Esposito A, Coppersmith N, Pantel H, Reddy V, Leeds I, Mongiu A. Coding the issue: low anterior resection syndrome following rectal cancer treatment. Frontiers In Surgery 2024, 11: 1503410. PMID: 39624463, PMCID: PMC11609209, DOI: 10.3389/fsurg.2024.1503410.Peer-Reviewed Original ResearchClinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma
Dunne E, Fick C, Mastrogiacomo B, Tan K, Toumbacaris N, Vanstraelen S, Rocco G, Chaft J, Iyengar P, Gomez D, Adusumilli P, Park B, Isbell J, Bott M, Sihag S, Molena D, Huang J, Jones D. Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma. JTCVS Open 2024, 22: 458-469. PMID: 39780816, PMCID: PMC11704575, DOI: 10.1016/j.xjon.2024.09.030.Peer-Reviewed Original ResearchResection of lung adenocarcinomaMaximum standardized uptake valueDevelopment of brain metastasesBrain metastasesStandardized uptake valueNeoadjuvant therapyLung adenocarcinomaAssociated with developmentLymphovascular invasionTP53 mutationsUptake valueCumulative incidence of brain metastasesMarker of aggressive tumor biologyHighest maximum standardized uptake valueLack of extracranial metastasesIncidence of brain metastasesNext-generation sequencingPanel next-generation sequencingAssociated with better survivalStage III diseaseMedian follow-upAggressive tumor biologyBetter performance statusAssociated with brain metastasisStereotactic radiosurgeryModeling lung adenocarcinoma metastases using patient-derived organoids
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, Chow-Tsang L, Tian H, Mastrogiacomo B, He D, Connolly J, Lengel H, Caso R, Dunne E, Fick C, Rocco G, Sihag S, Isbell J, Bott M, Li B, Lito P, Brennan C, Bilsky M, Rekhtman N, Adusumilli P, Mayo M, Imielinski M, Jones D. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Reports Medicine 2024, 5: 101777. PMID: 39413736, PMCID: PMC11513837, DOI: 10.1016/j.xcrm.2024.101777.Peer-Reviewed Original ResearchConceptsMetastasis modelLung adenocarcinomaAutologous peripheral blood mononuclear cellsEarly-stage lung cancerMechanisms of drug resistancePeripheral blood mononuclear cellsBlood mononuclear cellsEfficacy of treatmentLung cancer metastasisLung adenocarcinoma metastasisDistant metastasisStudy clonalityAdenocarcinoma metastasisLung cancerMononuclear cellsDrug resistanceMetastasisSuppress metastasisIndividual patientsTumor evolutionCancer metastasisHuman metastasesPatientsBiological featuresRNA sequencingLate recurrence of completely resected stage I to IIIA lung adenocarcinoma
Fick C, Dunne E, Toumbacaris N, Tan K, Mastrogiacomo B, Park B, Adusumilli P, Molena D, Gray K, Sihag S, Huang J, Bott M, Rocco G, Isbell J, Jones D. Late recurrence of completely resected stage I to IIIA lung adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 445-453.e3. PMID: 38950771, PMCID: PMC11682191, DOI: 10.1016/j.jtcvs.2024.06.026.Peer-Reviewed Original ResearchAggressive pathological featuresLate recurrenceLung adenocarcinomaFollow-upPathological featuresAssociated with late recurrenceElevated risk of recurrenceFactors associated with late recurrenceRetrospective analysis of patientsRecurrence of lung adenocarcinomaHistory of lung cancerStage IIIA diseaseTime of resectionRisk of recurrenceAnalysis of patientsGenomic mutationsNeoadjuvant therapyIIIA diseaseEarly recurrenceClinicopathological variablesLogistic regression modelsRetrospective analysisLung cancerRecurrencePatientsHigh-risk features associated with recurrence in stage I lung adenocarcinoma
Fick C, Dunne E, Vanstraelen S, Toumbacaris N, Tan K, Rocco G, Molena D, Huang J, Park B, Rekhtman N, Travis W, Chaft J, Bott M, Rusch V, Adusumilli P, Sihag S, Isbell J, Jones D. High-risk features associated with recurrence in stage I lung adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 436-444.e6. PMID: 38788834, PMCID: PMC11582076, DOI: 10.1016/j.jtcvs.2024.05.009.Peer-Reviewed Original ResearchCumulative incidence of recurrenceStage I lung adenocarcinomaIncidence of recurrenceClinicopathological featuresStage I LUADCumulative incidenceHighest maximum standardized uptake valueMaximum standardized uptake valueRetrospective analysis of patientsHigh risk of recurrenceHigh riskHistory of lung cancerStage I diseaseStandardized uptake valueVisceral pleural invasionHigh-risk featuresHazard of recurrenceAssociated with recurrenceFeatures associated with recurrenceRisk of recurrenceAnalysis of patientsPrognosis of patientsDay of surgeryR0 resectionSublobar resectionImmunotherapy for Resectable Locally Advanced Esophageal Carcinoma
Fick C, Dunne E, Sihag S, Molena D, Cytryn S, Janjigian Y, Wu A, Worrell S, Hofstetter W, Jones D, Gray K. Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma. The Annals Of Thoracic Surgery 2024, 118: 130-140. PMID: 38408631, PMCID: PMC11194153, DOI: 10.1016/j.athoracsur.2024.02.021.Peer-Reviewed Original ResearchLocally advanced esophagealImmune checkpoint inhibitorsDisease-free survivalGastroesophageal junctionPerioperative immunotherapyAdvanced esophagealNeoadjuvant chemoradiotherapyEsophageal carcinomaLocally advanced esophageal carcinomaPooled adverse event rateLocally advanced esophageal cancerPathologic complete response rateResponse rateDual checkpoint inhibitionGastroesophageal junction carcinomaAdvanced esophageal carcinomaComplete response rateAdvanced esophageal cancerEsophageal squamous cell carcinomaGastroesophageal junction cancerR0 resection rateResectable esophageal carcinomaPhase III trialsSquamous cell carcinomaAdverse event ratesThe Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Dunne E, Fick C, Isbell J, Chaft J, Altorki N, Park B, Spicer J, Forde P, Gomez D, Iyengar P, Harpole D, Stinchcombe T, Liberman M, Bott M, Adusumilli P, Huang J, Rocco G, Jones D. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. The Annals Of Thoracic Surgery 2024, 118: 119-129. PMID: 38316378, PMCID: PMC11194155, DOI: 10.1016/j.athoracsur.2024.01.024.Peer-Reviewed Original ResearchResected non-small cell lung cancerNon-small cell lung cancerAdvanced non-small cell lung cancerImmune checkpoint inhibitorsPhase III trialsCell lung cancerICI therapyPerioperative immunotherapyIII trialsLocally advanced non-small cell lung cancerTreatment of resectable non-small cell lung cancerLung cancerLong-term survival of patientsPathologic complete response rateUnited States Food and Drug Administration approvalRandomized phase III trialClinical trials of immunotherapyTreatment of non-small cell lung cancerFood and Drug Administration approvalImpairs surgical outcomesComplete response rateSignificant survival benefitTrials of immunotherapySurvival of patientsDrug Administration approval
2023
Lung resection after initial nonoperative treatment for non–small cell lung cancer
Dunne E, Fick C, Tan K, Toumbacaris N, Mastrogiacomo B, Adusumilli P, Rocco G, Molena D, Huang J, Park B, Bott M, Rusch V, Sihag S, Isbell J, Chaft J, Li B, Gomez D, Rimner A, Bains M, Jones D. Lung resection after initial nonoperative treatment for non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2023, 168: 364-373.e10. PMID: 38042400, PMCID: PMC11136875, DOI: 10.1016/j.jtcvs.2023.11.040.Peer-Reviewed Original ResearchEP07.04-04 High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma
Fick C, Dunne E, Mastrogiacomo B, Tan K, Toumbacaris N, Adusumilli P, Rocco G, Molena D, Huang J, Park B, Bott M, Rusch V, Sihag S, Isbell J, Jones D. EP07.04-04 High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma. Journal Of Thoracic Oncology 2023, 18: s544-s545. DOI: 10.1016/j.jtho.2023.09.1017.Peer-Reviewed Original ResearchGenomic profiling and metastatic risk in early-stage non–small cell lung cancer
Fick C, Dunne E, Lankadasari M, Mastrogiacomo B, Asao T, Vanstraelen S, Liu Y, Sanchez-Vega F, Jones D. Genomic profiling and metastatic risk in early-stage non–small cell lung cancer. JTCVS Open 2023, 16: 9-16. PMID: 38204702, PMCID: PMC10775106, DOI: 10.1016/j.xjon.2023.10.016.Peer-Reviewed Original Research